Hospital Universitario de Salamanca -ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2024

  1. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

    Annals of Hematology

2023

  1. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Tyrosine kinase inhibitor dose reduction during the management ofaccelerated phase chronic myeloid leukemia

    Leukemia Research

2020

  1. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications

    International Journal of Cancer, Vol. 147, Núm. 10, pp. 2780-2792

  2. Comprehensive custom ngs panel validation for the improvement of the stratification of b-acute lymphoblastic leukemia patients

    Journal of Personalized Medicine, Vol. 10, Núm. 3, pp. 1-21

  3. Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. e513-e522

2019

  1. Successful bendamustine desensitization for a delayed-type hypersensitivity reaction

    Journal of Investigational Allergology and Clinical Immunology, Vol. 29, Núm. 1, pp. 68-69

2016

  1. Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome

    PloS one, Vol. 11, Núm. 2, pp. e0148972

2015

  1. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

2014

  1. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification

    Leukemia, Vol. 28, Núm. 1, pp. 166-173

2013

  1. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia

    European Journal of Haematology, Vol. 91, Núm. 3, pp. 236-241

2011

  1. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

    Blood, Vol. 117, Núm. 13, pp. 3613-3616

2008

  1. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma

    British Journal of Haematology, Vol. 141, Núm. 2, pp. 212-215

  2. Transient t(11;17)(q14;q12) in patient with chronic myelogenous leukemia in complete molecular response

    Cancer Genetics and Cytogenetics

2006

  1. Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain

    Leukemia Research, Vol. 30, Núm. 8, pp. 943-948

  2. The association of increased p14 ARF/p16 INK4a and p15 INK4b gene expression with proliferative activity and the clinical course of multiple myeloma

    Haematologica, Vol. 91, Núm. 11, pp. 1551-1554

2005

  1. Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11

    Cancer Genetics and Cytogenetics, Vol. 160, Núm. 1, pp. 68-72

2002

  1. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma

    Hematology Journal, Vol. 3, Núm. 1, pp. 43-48

2000

  1. Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic stem cell transplantation

    Bone Marrow Transplantation, Vol. 26, Núm. 11, pp. 1229-1230